Vascular patent for HealthLinx
Wednesday, 17 September, 2008
HealthLinx [ASX: HTX] has been granted a US patent related to the company's vascular permeability program.
Licensed from the University of Virginia, the patent is related to the inhibition of the p21 activated kinase pathway as a treatment for disorders caused by aberrant vascular permeability.
It has widespread potential applications, including ischemia, stroke or burns.
The patent also forms part of the drug candidate CR014, a potential treatment for acute respiratory distress syndrome (ARDS) that the company is developing with the Canadian-based InSymbiosis.
No effective therapeutic treatments are available for the disease, which has a morbidity rate as high as 40 percent.
HealthLinx and InSymbiosis are preparing to embark on a preclinical development program for CR014.
NSW Govt delivers foot-and-mouth vaccine to protect livestock
A biodegradable vaccine to protect livestock from foot-and-mouth disease has been developed as...
Scientists optimise delivery of mRNA to target cells
A highly versatile new method captures and attaches antibodies to the surface of mRNA-loaded...
'Anti-reward' brain network helps explain cocaine addiction
A new study identifies a specific 'anti-reward' network deep in the brain that undergoes...
